Chordia Therapeutics Inc. AI Stock Analysis
Want to see JP:190A full AI Analyst Report?
Chordia Therapeutics Inc. (190A) AI Stock Analysis
Chordia Therapeutics Inc.
(TSE/TYO:190A)
The overall score is very low, driven primarily by extremely weak financial performance with no revenue and high cash burn, compounded by bearish technicals showing strong downward momentum. The negative P/E ratio and lack of dividend yield further confirm the stock's high-risk, speculative nature.
Chordia Therapeutics Inc. (190A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.54B
- Dividend Yield
- ―
- Average Volume (3M)
- 515.94K
- Price to Earnings (P/E)
- -2.3
- Beta (1Y)
- 0.70
- Revenue Growth
- ―
- EPS Growth
- 24.21%
- Country
- Japan
- Employees
- 20
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Chordia Therapeutics Inc. Business Overview & Revenue Model
Company Description
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relap...
How the Company Makes Money
Chordia Therapeutics’ primary business model is typical of an R&D-stage biotech company: it invests in developing proprietary drug candidates and seeks to monetize them through a combination of (a) upfront payments and milestone payments from licensi...
Chordia Therapeutics Inc. Financial Statement Overview
Summary
Financial performance is very weak. The company is pre-revenue with no sales in the recent period, generating significant operating and net losses. The only positive is a debt-free balance sheet, but equity is rapidly eroding and cash burn is substantial, indicating a high-risk, speculative profile dependent on external funding.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Aug 2026 | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 2.50B | 0 |
| Gross Profit | 0 | 0 | -1.43B | -4.09M | 2.49B | -3.15M |
| EBITDA | -1.46B | -1.47B | -1.79B | -1.82B | 218.10M | -1.77B |
| Net Income | -1.46B | -1.46B | -1.79B | -1.83B | 223.34M | -1.78B |
Balance Sheet | ||||||
| Total Assets | 2.11B | 2.11B | 2.68B | 4.63B | 4.91B | 4.50B |
| Cash, Cash Equivalents and Short-Term Investments | 2.05B | 2.05B | 2.55B | 4.33B | 4.80B | 4.25B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 188.84M | 188.84M | 244.34M | 471.07M | 408.24M | 221.41M |
| Stockholders Equity | 1.93B | 1.93B | 2.44B | 4.16B | 4.50B | 4.28B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.42B | -1.84B | -1.94B | 543.01M | -1.72B |
| Operating Cash Flow | 0 | -1.42B | -1.84B | -1.94B | 543.73M | -1.70B |
| Investing Cash Flow | 0 | -2.28M | -5.33M | -10.96M | 345.00K | -14.70M |
| Financing Cash Flow | 0 | 924.13M | 61.58M | 1.48B | 0 | 3.98B |
Chordia Therapeutics Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:190A, the sentiment is Negative. The current price of 46.00 is below the 20-day moving average (MA) of 49.40, below the 50-day MA of 59.86, and below the 200-day MA of 96.67, indicating a bearish trend. The MACD of -4.66 indicates Negative momentum. The RSI at 29.15 is Positive, neither overbought nor oversold. The STOCH value of 42.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:190A.
Chordia Therapeutics Inc. Peers Comparison
Overall Rating
JP:219A75.8Outperform
JP:493171Outperform
JP:334959.9Neutral
JP:279643Neutral- JP:190A38Underperform
JP:489037Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:219A | 76Outperform | JPY 69.36B | -99.08 | ― | ― | ― | ― |
| JP:4931 | 71Outperform | JPY 42.61B | 13.17 | ― | 2.88% | 5.63% | 37.65% |
| JP:3349 | 60Neutral | JPY 496.38B | 15.67 | ― | 1.29% | 8.99% | 3.61% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:2796 | 43Neutral | JPY 5.94B | 59.72 | ― | 2.76% | 7.64% | ― |
| JP:190A | 38Underperform | JPY 3.54B | -2.28 | ― | ― | ― | 24.21% |
| JP:4890 | 37Underperform | JPY 6.05B | -8.29 | ― | ― | -39.46% | -317.84% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:190A | Chordia Therapeutics Inc. | 46.00 | -61.00 | -57.01% | |
| JP:2796 | Pharmarise Holdings Corp. | 507.00 | -18.84 | -3.58% | |
| JP:3349 | COSMOS Pharmaceutical Corporation | 6437.00 | -929.03 | -12.61% | |
| JP:4890 | Tsubota Laboratory Incorporated | 217.00 | -127.00 | -36.92% | |
| JP:4931 | Shinnihonseiyaku Co., Ltd. | 2040.00 | -13.07 | -0.64% | |
| JP:219A | Heartseed, Inc. | 2885.00 | 1165.00 | 67.73% |
Chordia Therapeutics Inc. Corporate Events
Chordia Therapeutics Moves to Clean Up Deficit Through Capital Reserve Reclassification
Chordia Therapeutics Inc. has approved a restructuring of its equity accounts by reducing its capital reserve by JPY 1,455,144,346 and transferring the same amount to other capital surplus. In a subsequent step, this newly increased other capital sur...
Chordia Therapeutics Maps Out FY2026 Results and FY2027 Priorities
Chordia Therapeutics Inc. released a financial results presentation for the fiscal year ended August 2026, outlining its corporate overview, key highlights, and review of operations. The materials also detail FY2026 financial performance, progress ac...
Chordia Therapeutics Narrows Annual Loss but Maintains Cautious Outlook
Chordia Therapeutics reported a non-consolidated operating loss of ¥1,473 million and a net loss of ¥1,455 million for the fiscal year ended August 31, 2026, with basic earnings per share improving to minus ¥19.74 from minus ¥26.03 a year earlier. To...
Chordia Therapeutics Secures AMED Grant to Accelerate Global Development of Rogocekib
Chordia Therapeutics has received a significant boost for its flagship oncology program, announcing that its rogocekib (CTX-712) project was selected for Japan’s FY2026 Advanced Research and Development Program for Medical Innovation. The AMED-backed...
Chordia Therapeutics Completes Initial Expansion Cohort Enrollment for Rogocekib Trial
Chordia Therapeutics Inc., a Fujisawa-based oncology-focused biopharmaceutical developer, is advancing a portfolio of targeted cancer therapies led by its clinical-stage candidate rogocekib. The company is positioning itself in the growth market for...
Chordia Wins Japan Orphan Drug Status for Lead AML Therapy rogocekib
Chordia Therapeutics has secured Orphan Drug Designation in Japan for its lead candidate rogocekib, a CLK inhibitor, for the treatment of relapsed or refractory acute myeloid leukemia, following a similar designation previously granted by the U.S. FD...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026